Results 291 to 300 of about 9,264,457 (358)

Review of the anatomical basis for predicting plutonium alpha particle radiation induced osteogenic cancers

The Anatomical Record, EarlyView.
Abstract Plutonium was discovered and first synthesized in the early 1940's. Several isotopes of plutonium are used in nuclear technologies, 238Pu for heat generation and 239Pu for energy production and weapons. Both isotopes emit alpha particles, which pose a significant radiation hazard when incorporated into the body.
Scott C. Miller
wiley   +1 more source

Predictors of Remission in Graves' Disease Patients Treated With Antithyroid Drugs: A Retrospective Study. [PDF]

Cureus
Alzahrani RS, Aljabri YH, Alzahrani WS, Fatani FM, Alghamdi LJ, Alsudais AS, Radi S.   +6 more
europepmc   +1 more source

The Free Thyroxine-to-Thyroid Stimulating Hormone Ratio: A Potential Diagnostic Marker for Graves' Disease. [PDF]

Int J Endocrinol Metab
Binti Rahmat N, Tuan Ismail TS, Bin Md Muslim MZ, Bin Wan Zain WMS, Bin Zakaria AZ, Bin Yusoff MY.   +5 more
europepmc   +1 more source

Analysis of Cost and Treatment Effects in the Care Given for Graves' Disease: A Swedish Cost-Utility Analysis. [PDF]

Endocrinol Diabetes Metab
Lindholm L, Sjölin G, Jonsson A, Abraham-Nordling M, Wallin G, TT‐12 Study Group, Nyström HF.   +6 more
europepmc   +1 more source

Integrating shear wave elastography into clinical prediction of Graves' disease recurrence: a novel risk scoring system. [PDF]

Front Endocrinol (Lausanne)
Zha XY, Xu ZH, Dong JJ, Xie LX, Lai PB, Wei CS, Zheng HQ, Huang DB, Wu JZ.   +8 more
europepmc   +1 more source

Radioiodine Therapy of Graves' Disease in Women with Childbearing Potential and the Pre-Conceptional Counseling About Antithyroid Drugs. [PDF]

J Clin Med
Dietlein M, Schmidt M, Drzezga A, Kobe C.   +3 more
europepmc   +1 more source

Correction to: Role of Lugol solution before total thyroidectomy for Graves' disease: randomized clinical trial. [PDF]

Br J Surg
europepmc   +1 more source

Assessment of Hearing Dysfunction in Patients With Graves' Disease and Thyroid Eye Disease Without or With Teprotumumab.

J Clin Endocrinol Metab
Smith TJ, Holt RJ, Fu Q, Qashqai A, Barretto N, Conrad E, Brant JA.   +6 more
europepmc   +1 more source